Steiner Murphy M, Calandruccio James H
Department of Orthopaedic Surgery and Biomedical Engineering, University of Tennessee-Campbell Clinic, 1211 Union Avenue, Suite 510, Memphis, TN 38104, USA.
Department of Orthopaedic Surgery and Biomedical Engineering, University of Tennessee-Campbell Clinic, 1211 Union Avenue, Suite 510, Memphis, TN 38104, USA.
Orthop Clin North Am. 2017 Jul;48(3):343-349. doi: 10.1016/j.ocl.2017.03.010. Epub 2017 Apr 7.
Orthobiologics are not used as frequently in the hand and wrist as in other sites. The most frequently reported is the use of bone morphogenetic protein for the treatment of Kienböck disease. Animal studies have described improved tendon healing with the use of platelet-rich plasma (PRP), but no clinical studies have confirmed these results. PRP has been reported to produce improvements in the outcomes of distal radial fractures and osteoarthritis of the trapeziometacarpal in small numbers of patients. The use of orthobiologics in the hand and wrist are promising, but clinical trials are necessary to establish efficacy and safety.
与其他部位相比,骨科生物制剂在手部和腕部的使用频率较低。最常报道的是使用骨形态发生蛋白治疗月骨无菌性坏死。动物研究表明,使用富血小板血浆(PRP)可改善肌腱愈合,但尚无临床研究证实这些结果。据报道,PRP在少数桡骨远端骨折和第一腕掌关节骨关节炎患者中可改善治疗效果。骨科生物制剂在手部和腕部的应用前景广阔,但需要进行临床试验来确定其有效性和安全性。